Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioengineering
Reports summarize bioengineering research from University of Ulm
January 13th, 2009
According to recent research published in the journal Clinical Cancer Research, "Auger electron emitting radiopharmaceuticals are attractive for targeted nanoirradiation therapy, provided that DNA of malignant cells is selectively addressed. Here, we examine 5-[(123/125/131)] iodo-4 '-thio-2 '-deoxyuridine (ITdU) for targeting DNA in tumor cells in a HL60 xenograft severe combined immunodeficient mouse model." "Thymidine kinase and phosphorylase assays were done to determine phosphorylation and glycosidic bond cleavage of lTdU, respectively. The biodistribution and DNA incorporation of ITdU were determined in severe combined immunodeficient mice bearing HL60...
Source: Cancer Weekly (2009-01-13)
|
